Ximelagatran (Exanta): Alternative to Warfarin?(Pharmacology Notes) (Drug Overview)

Ximelagatran (Exanta): Alternative to Warfarin?(Pharmacology Notes) (Drug Overview)

For decades, the standards of antithrombotic therapy have been heparin and coumarin compounds, primarily warfarin (1). Other newer approaches include low-molecular-weight heparins, fondaparinux, lepirudin, argatroban, and melagatran (investigational). Although existing treatments are effective, they have many limitations. A safer, more convenient therapy is needed. Ximelagatran is the first oral treatment in a new World Health Organization class of direct thrombin inhibitors and is the first new oral anticoagulant since the introduction of warfarin almost 60 years ago (2). It was submitted to the Food and Drug Administration (FDA) for approval in December 2003 (3). Each year, nearly 4 million people worldwide experience a primary thrombotic event, and those at greatest risk include people with atrial fibrillation, those who have experienced a previous cardiac event such as a myocardial infarction, and patients who have recently undergone orthopaedic surgery, such as total hip or knee replacement surgery (4). Current mainstays of therapy for preventing or treating thrombosis are not ideal. Warfarin, although available in an oral form, has a slow onset of action, interacts with numerous foods and drugs, and requires intensive monitoring of coagulation with frequent dose adjustments. Heparins, fondaparinux, lepirudin, argatroban, and melagatran (investigational) are limited by their route of administration, especially in an outpatient setting, as all are administered parenterally (5, 6). Ximelagatran, a prodrug of melagatran, is an orally administered direct inhibitor of both free and clot-bound thrombin. It is rapidly absorbed and quickly converted to its active form, melagatran, with stable and reproducible pharmacokinetic properties. No clinically significant interactions with food or cytochrome P450-metabolized drugs have been reported for ximelagatran, and the drug requires no monitoring (7).

Ximelagatran (Exanta): Alternative to Warfarin?(Pharmacology Notes) (Drug Overview)



Here is Download Link

The Vein Book


The Vein Book Read Online Download

Author by : John J. Bergan
Languange Used : en
Release Date : 2006-12-14
Publisher by : Elsevier






Attrition In The Pharmaceutical Industry


Attrition In The Pharmaceutical Industry Read Online Download

Author by : Alexander Alex
Languange Used : en
Release Date : 2015-10-26
Publisher by : John Wiley & Sons






Anticoagulation Management


Anticoagulation Management Read Online Download

Author by : Anne Rose
Languange Used : en
Release Date : 2015-10-02
Publisher by : Springer






Anticoagulants Antiplatelets And Thrombolytics


Anticoagulants Antiplatelets And Thrombolytics Read Online Download

Author by : Shaker A. Mousa
Languange Used : en
Release Date : 2010-08-17
Publisher by : Humana PressInc






Bioactive Carboxylic Compound Classes


Bioactive Carboxylic Compound Classes Read Online Download

Author by : Clemens Lamberth
Languange Used : en
Release Date : 2016-08-22
Publisher by : John Wiley & Sons






Color Atlas Of Pharmacology


Color Atlas Of Pharmacology Read Online Download

Author by : Heinz Lüllmann
Languange Used : en
Release Date : 2000
Publisher by : Thieme






Human Drug Metabolism


Human Drug Metabolism Read Online Download

Author by : Michael D. Coleman
Languange Used : en
Release Date : 2010-03-30
Publisher by : John Wiley & Sons






Leave a Reply

Your email address will not be published. Required fields are marked *